More Posts
How Challenging Low Quality Patents is Lowering Drug Prices
The FTC made headlines in May when it announced it was challenging over 300 “junk” patents in the FDA’s “Orange Book,” including patents on popular drugs like Ozempic and Victoza. With this ...
Incremental Progress on Valve
In March, U.S. Patent and Trademark Office Director Kathi Vidal vacated earlier Patent Trial and Appeal Board (PTAB) decisions that denied patent validity challenges brought by Honda Motor Co., Genera...
Congress Wants to Revive Patents but May Strangle Innovation and Damage Health Care Access Instead
This post, written by Wayne Brough, initially appeared in the R Street’s Real Solutions Blog.
Patent eligibility, or the fundamental question of what is patentable, is currently under congression...